W e read with great interest the recent article by Leeds et al. (1) regarding the effect of the presence of celiac disease (CD) on glycometabolic parameters in type 1 diabetic subjects and, above all, on diabetes-related microvascular complications. Indeed, several epidemiological and genetic studies strongly suggest a morethan-random association between type 1 diabetes and CD (2,3), but no current guidelines encourage different approaches in patients with the coexistence of the two diseases in terms of glycometabolic targets and/or screening of vascular complications.
We recently published a similar study (case-control) (4) that showed that the presence of CD is also associated with an increased intima-media thickness of the carotid arteries, a well-known intermediate marker of endothelial dysfunction and macrovascular disease. Therefore, although the intrinsic nature of the two studies does not allow for a definitive demonstration of a cause and effect relationship between CD and diabetes-related micro-and macrovascular complications, we strongly believe that: 1) Type 1 diabetic patients with an early presence of micro/macrovascular complications (in particular at the diagnosis) should be screened for CD; this is also true in the case of persistently high HbA 1c values ("brittle diabetes").
2) The coexistence of CD and diabetes causes a worsening of metabolic control, above all if the former is not treated, which probably puts these patients in a higher-risk category. This is why it is reasonable to consider a more frequent screening for complications and to define different glycometabolic targets in this group of subjects. The consequence could be the application of different lowering-risk strategies, for example an early intervention with a statin and/or aspirin.
We are well aware that these are, to date, just speculations. However, a growing body of evidence, including these two studies, suggests that we urgently need randomized controlled trials to explore these hypotheses. 
